FISH(Fluorescent In Situ Hybridization) 이미징 시스템 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Fluorescence In Situ Hybridization Imaging Systems Market Growth & Trends:

The global fluorescence in situ hybridization imaging systems market size is expected to reach USD 2.14 billion by 2030, expanding at a CAGR of 8.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. Increasing R&D investments pertaining to in vitro diagnostics are expected to drive the Fluorescence In Situ Hybridization (FISH) imaging systems market. The presence of government organizations, such as the European Diagnostic Manufacturers Association that focuses on the development and growth of the in vitro diagnostics market in Europe, is also contributing to growth.

Furthermore, FISH imaging systems are gaining popularity in diagnostics for the determination of suspected diseases caused by pathogens or bacteria. Increasing incidence of genetic diseases, such as lymphoma, solid tumors, leukemia, autism, and other developmental syndromes, is also expected to boost adoption. Growing penetration of fluoroscopy, microscopes, illuminators, and CCD cameras in testing for infectious diseases is expanding growth opportunities for these systems. Increasing prevalence of diseases with chromosomal aberrations, such as cancer and genetic abnormalities, as well as unmet diagnostic & clinical needs in developing countries, is anticipated to drive the market.

Moreover, increasing demand for rapid, sensitive, & accurate diagnostic techniques for validation of diseases, coupled with rising awareness, increase in healthcare expenditure, and extensive R&D for the development of novel imaging systems are also expected to drive growth over the forecast period.

Fluorescence In Situ Hybridization Imaging Systems Market Report Highlights:

• Instruments held the largest market, whereas FISH imaging services are expected to grow at the fastest rate during the forecast period
• At present, the market penetration of FISH imaging in cancer diagnostics is very high, hence the diagnostic laboratories segment accounted for larger revenues
• Cancer diagnosis held the largest revenue share owing to increasing incidence of cancer, thus fueling the adoption of FISH imaging systems
• Among end-use segments, companion diagnostics is expected to witness faster growth than research and diagnostic segments
• Diagnostic laboratories held the dominant position in 2016 as these systems are predominantly used in various clinical studies for visualization of precancerous lesions in cervical cancer, assessing the risk of human papillomavirus, and for detection of leukemia, myelodysplastic syndrome, multiple myeloma, & chromosomal abnormalities
• North America held the largest revenue share owing to extensive adoption of these solutions in research and development across this region
• Asia Pacific is anticipated to exhibit lucrative CAGR over the forecast period due to the increase in investments by manufacturers & governments, supportive government initiatives in the biotechnology sector, and the presence of a large number of untapped opportunities
• The industry is highly competitive with a limited number of players holding a majority of the overall revenues. Some of the most notable market participants are Euroclone SpA, TissueGnostics GmbH, Agilent Technologies, Inc., Abnova Taiwan Corp, BioGenex Laboratories Inc., o Bio-View Ltd and General Electric Company. They account for a considerable share of the industry

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Fluorescence In Situ Hybridization Imaging Systems Variables, Trends, & Scope

• 3.1. Market Introduction/Lineage Outlook
• 3.2. Market Size and Growth Prospects (USD Million)
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
  • 3.3.2. Market Restraints Analysis
• 3.4. Fluorescence In Situ Hybridization Imaging Systems Analysis Tools
  • 3.4.1. Porter's Analysis
    • 3.4.1.1. Bargaining power of the suppliers
    • 3.4.1.2. Bargaining power of the buyers
    • 3.4.1.3. Threats of substitution
    • 3.4.1.4. Threats from new entrants
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Economic and Social landscape
    • 3.4.2.3. Technological landscape
    • 3.4.2.4. Environmental landscape
    • 3.4.2.5. Legal landscape

Chapter 4. Fluorescence In Situ Hybridization Imaging Systems Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Fluorescence In Situ Hybridization Imaging Systems Market: Product Movement Analysis, 2023 & 2030 (USD Million)
• 4.3. Instruments
  • 4.3.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.3.2. Microscopes
    • 4.3.2.1. Microscopes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.3.3. Automated cell analyzers
    • 4.3.3.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.3.4. Others
    • 4.3.4.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.4. Consumables & Accessories
  • 4.4.1. Consumables & Accessories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Services
  • 4.5.1. Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Software
  • 4.6.1. Software Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Fluorescence In Situ Hybridization Imaging Systems: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Fluorescence In Situ Hybridization Imaging Systems Market: Application Movement Analysis, 2023 & 2030 (USD Million)
• 5.3. Cancer Diagnosis
  • 5.3.1. Cancer Diagnosis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.2. Lung Cancer
    • 5.3.2.1. Lung Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.3. Breast Cancer
    • 5.3.3.1. Breast Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.4. Others
    • 5.3.4.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.4. Genetic Disease Diagnosis
  • 5.4.1. Genetic Disease Diagnosis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Others
  • 5.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Fluorescence In Situ Hybridization Imaging Systems: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Fluorescence In Situ Hybridization Imaging Systems Market: End Use Movement Analysis, 2023 & 2030 (USD Million)
• 6.3. Diagnostic Laboratories
  • 6.3.1. Diagnostic Laboratories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.4. Research & Academic Institutes
  • 6.4.1. Research & Academic Institutes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Others
  • 6.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Fluorescence In Situ Hybridization Imaging Systems Market: Regional Estimates & Trend Analysis

• 7.1. Fluorescence In Situ Hybridization Imaging Systems Share, By Region, 2023 & 2030 (USD Million)
• 7.2. North America
  • 7.2.1. North America Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.2. U.S.
    • 7.2.2.1. U.S. Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.3. Canada
    • 7.2.3.1. Canada Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.4. Mexico
    • 7.2.4.1. Mexico Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.3. Europe
  • 7.3.1. Europe Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.2. U.K.
    • 7.3.2.1. U.K. Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.3. Germany
    • 7.3.3.1. Germany Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.4. France
    • 7.3.4.1. France Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.5. Italy
    • 7.3.5.1. Italy Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.6. Spain
    • 7.3.6.1. Spain Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.7. Denmark
    • 7.3.7.1. Denmark Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.8. Sweden
    • 7.3.8.1. Sweden Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.9. Norway
    • 7.3.9.1. Sweden Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.4. Asia Pacific
  • 7.4.1. Asia Pacific Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.2. Japan
    • 7.4.2.1. Japan Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. China
    • 7.4.3.1. China Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.4. India
    • 7.4.4.1. India Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.5. South Korea
    • 7.4.5.1. South Korea Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.6. Thailand
    • 7.4.6.1. Thailand Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Latin America
  • 7.5.1. Latin America Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2. Brazil
    • 7.5.2.1. Brazil Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. Argentina
    • 7.5.3.1. Argentina Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Middle East and Africa
  • 7.6.1. Middle East and Africa Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.2. South Africa
    • 7.6.2.1. South Africa Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. Saudi Arabia
    • 7.6.3.1. Saudi Arabia Fluorescence In Situ Hybridization Imaging Systems and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.4. UAE
    • 7.6.4.1. Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.5. Kuwait
    • 7.6.5.1. Kuwait Fluorescence In Situ Hybridization Imaging Systems Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis by Key Market Participants
• 8.2. Company Categorization
• 8.3. Company Heat Map Analysis
• 8.4. Company Profiles
  • 8.4.1. Euroclone SpA
    • 8.4.1.1. Participant's Overview
    • 8.4.1.2. Financial Performance
    • 8.4.1.3. Product Benchmarking
    • 8.4.1.4. Recent Developments/ Strategic Initiatives
  • 8.4.2. TissueGnostics GmbH
    • 8.4.2.1. Participant's Overview
    • 8.4.2.2. Financial Performance
    • 8.4.2.3. Product Benchmarking
    • 8.4.2.4. Recent Developments/ Strategic Initiatives
  • 8.4.3. Agilent Technologies, Inc.
    • 8.4.3.1. Participant's Overview
    • 8.4.3.2. Financial Performance
    • 8.4.3.3. Product Benchmarking
    • 8.4.3.4. Recent Developments/ Strategic Initiatives
  • 8.4.4. Abnova Taiwan Corp
    • 8.4.4.1. Participant's Overview
    • 8.4.4.2. Financial Performance
    • 8.4.4.3. Product Benchmarking
    • 8.4.4.4. Recent Developments/ Strategic Initiatives
  • 8.4.5. BioGenex Laboratories Inc
    • 8.4.5.1. Participant's Overview
    • 8.4.5.2. Financial Performance
    • 8.4.5.3. Product Benchmarking
    • 8.4.5.4. Recent Developments/ Strategic Initiatives
  • 8.4.6. Leica Biosystems Nussloch GmbH
    • 8.4.6.1. Participant's Overview
    • 8.4.6.2. Financial Performance
    • 8.4.6.3. Product Benchmarking
    • 8.4.6.4. Recent Developments/ Strategic Initiatives
  • 8.4.7. Bio-View Ltd
    • 8.4.7.1. Participant's Overview
    • 8.4.7.2. Financial Performance
    • 8.4.7.3. Product Benchmarking
    • 8.4.7.4. Recent Developments/ Strategic Initiatives
  • 8.4.8. Thermo Fisher Scientific, Inc.
    • 8.4.8.1. Participant's Overview
    • 8.4.8.2. Financial Performance
    • 8.4.8.3. Product Benchmarking
    • 8.4.8.4. Recent Developments/ Strategic Initiatives
  • 8.4.9. MetaSystems Probes GmbH
    • 8.4.9.1. Participant's Overview
    • 8.4.9.2. Financial Performance
    • 8.4.9.3. Product Benchmarking
    • 8.4.9.4. Recent Developments/ Strategic Initiatives